149 related articles for article (PubMed ID: 34740578)
1. Effects of in-vitro modulation of TRPV1 activity on immune response of mice bearing metastatic breast carcinoma: Enhanced inflammatory response may hinder therapeutic potentials of TRPV1 agonists.
Erin N; Akman M
Life Sci; 2021 Dec; 287():120115. PubMed ID: 34740578
[TBL] [Abstract][Full Text] [Related]
2. Olvanil activates sensory nerve fibers, increases T cell response and decreases metastasis of breast carcinoma.
Erin N; Akman M; Aliyev E; Tanrıöver G; Korcum AF
Life Sci; 2022 Feb; 291():120305. PubMed ID: 35016880
[TBL] [Abstract][Full Text] [Related]
3. Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons.
Pecze L; Jósvay K; Blum W; Petrovics G; Vizler C; Oláh Z; Schwaller B
Biochim Biophys Acta; 2016 Aug; 1863(8):2054-64. PubMed ID: 27180305
[TBL] [Abstract][Full Text] [Related]
4. Role of sensory neurons, neuroimmune pathways, and transient receptor potential vanilloid 1 (TRPV1) channels in a murine model of breast cancer metastasis.
Erin N
Cancer Immunol Immunother; 2020 Feb; 69(2):307-314. PubMed ID: 31912230
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1.
Czikora Á; Lizanecz E; Bakó P; Rutkai I; Ruzsnavszky F; Magyar J; Pórszász R; Kark T; Facskó A; Papp Z; Édes I; Tóth A
Br J Pharmacol; 2012 Mar; 165(6):1801-1812. PubMed ID: 21883148
[TBL] [Abstract][Full Text] [Related]
6. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
7. Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis.
Ma L; Zhong J; Zhao Z; Luo Z; Ma S; Sun J; He H; Zhu T; Liu D; Zhu Z; Tepel M
Cardiovasc Res; 2011 Dec; 92(3):504-13. PubMed ID: 21908651
[TBL] [Abstract][Full Text] [Related]
8. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators.
Bishnoi M; Bosgraaf CA; Abooj M; Zhong L; Premkumar LS
Mol Pain; 2011 Jul; 7():52. PubMed ID: 21794120
[TBL] [Abstract][Full Text] [Related]
9. Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels.
Nazıroğlu M; Çiğ B; Blum W; Vizler C; Buhala A; Marton A; Katona R; Jósvay K; Schwaller B; Oláh Z; Pecze L
PLoS One; 2017; 12(6):e0179950. PubMed ID: 28640864
[TBL] [Abstract][Full Text] [Related]
10. Fas-associated factor 1 is a negative regulator in capsaicin induced cancer cell apoptosis.
Ghosh AK; Basu S
Cancer Lett; 2010 Jan; 287(2):142-9. PubMed ID: 19570606
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
Long DJ; Devantier HR; Brennan FX; Bryant RW; Salemme FR; Palmer RK
J Pharmacol Exp Ther; 2010 Feb; 332(2):525-30. PubMed ID: 19903834
[TBL] [Abstract][Full Text] [Related]
12. Modulation of neuroinflammation: Role and therapeutic potential of TRPV1 in the neuro-immune axis.
Kong WL; Peng YY; Peng BW
Brain Behav Immun; 2017 Aug; 64():354-366. PubMed ID: 28342781
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of TRPV1 ligands on nonspecific and enteroantigen-specific T cells from wild-type and Trpv1 KO mice.
Belmaáti MS; Diemer S; Hvarness T; Baumann K; Pedersen AE; Christensen RE; Claesson MH
Inflamm Bowel Dis; 2014 Jun; 20(6):1004-14. PubMed ID: 24788222
[TBL] [Abstract][Full Text] [Related]
14. Differences in the effects of four TRPV1 channel antagonists on lipopolysaccharide-induced cytokine production and COX-2 expression in murine macrophages.
Ninomiya Y; Tanuma SI; Tsukimoto M
Biochem Biophys Res Commun; 2017 Mar; 484(3):668-674. PubMed ID: 28153725
[TBL] [Abstract][Full Text] [Related]
15. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.
Tsuji F; Murai M; Oki K; Seki I; Ueda K; Inoue H; Nagelkerken L; Sasano M; Aono H
Eur J Pharmacol; 2010 Feb; 627(1-3):332-9. PubMed ID: 19878665
[TBL] [Abstract][Full Text] [Related]
16. Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.
Ursu D; Knopp K; Beattie RE; Liu B; Sher E
Eur J Pharmacol; 2010 Sep; 641(2-3):114-22. PubMed ID: 20576527
[TBL] [Abstract][Full Text] [Related]
17. TRPV1 mediates capsaicin-stimulated metabolic activity but not cell death or inhibition of interleukin-1β release in human THP-1 monocytes.
Kunde DA; Yingchoncharoen J; Jurković S; Geraghty DP
Toxicol Appl Pharmacol; 2018 Dec; 360():9-17. PubMed ID: 30244119
[TBL] [Abstract][Full Text] [Related]
18. Transient receptor potential vanilloid 1 agonists cause endoplasmic reticulum stress and cell death in human lung cells.
Thomas KC; Sabnis AS; Johansen ME; Lanza DL; Moos PJ; Yost GS; Reilly CA
J Pharmacol Exp Ther; 2007 Jun; 321(3):830-8. PubMed ID: 17332266
[TBL] [Abstract][Full Text] [Related]
19. Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.
McArthur JR; Finol-Urdaneta RK; Adams DJ
Br J Pharmacol; 2019 Jul; 176(13):2264-2278. PubMed ID: 30927254
[TBL] [Abstract][Full Text] [Related]
20. TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.
Li S; Bode AM; Zhu F; Liu K; Zhang J; Kim MO; Reddy K; Zykova T; Ma WY; Carper AL; Langfald AK; Dong Z
Carcinogenesis; 2011 May; 32(5):779-85. PubMed ID: 21349818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
